Curcumin (CUR) shows great potential in the management of alcohol-use disorders. However, the hydrophobicity and poor oral bioavailability result in the limited therapeutic efficacy of CUR against alcohol-induced tissue injury. Here, self-assembled Soluplus® micelles (Ms) were developed for the enhanced oral delivery of CUR. CUR-loaded Soluplus® micelles (CUR-Ms) were prepared using a thin-film hydration method and these micelles displayed nearly spherical shape with an average size of 62.80 ± 1.29 nm.
CUR in micelles showed the greater stability, solubility and dissolution than free CUR. With the increased water solubility of CUR-Ms and P glycoprotein inhibition of Soluplus®, the absorption rate constant (Ka) and apparent permeability coefficient (Papp) of CUR-Ms in intestines was respectively 3.50 and 4.10 times higher than that of free CUR. Pharmacokinetic studies showed that CUR-Ms significantly improved the oral bioavailability of CUR. Specifically, the AUC0–∞ and Cmax of CUR-Ms were increased by 9.45 and 47.38 folds compared to free CUR, respectively.
In mice with alcohol-induced tissue injury, the oral administration of CUR-Ms greatly reduced oxidative stress, and significantly defended liver and gastric mucosa from alcoholic damages. The results demonstrated CUR-Ms with good oral bioavailability could represent a promising strategy for the management of alcohol-induced tissue injury.
Article information: (2021) Self-assembled micelles enhance the oral delivery of curcumin for the management of alcohol-induced tissue injury, Pharmaceutical Development and Technology, DOI: 10.1080/10837450.2021.1950185









































All4Nutra




![Application of SeDeM Expert System in particle engineering design space of co-processed excipients. Stage I involves the characterization of Critical Material Attributes (CMAs) of both defective and corrective materials using SeDeM methodology [a]. Stage II: Computing the loading capacity of the corrective excipient using dilution potential equation proposed by the SeDeM Expert System [b]. Stage III: Selection of co-processing technique based on intrinsic material property and desired CMAs [c]. Stage IV: Evaluating the impact of co-processing by monitoring the critical behavior of the engineered composite with the decision on either to accept or reject the product [d]. Upon failing to meet up with the critical specifications or acceptance criteria, the process conditions in Stage III can be revalidated or modified. IPP: Parametric Profile Index, IGC: Good Compression Index, ψc: Compressibility function, ѱf: Flowability function](https://www.pharmaexcipients.com/wp-content/uploads/2021/07/Application-of-SeDeM-Expert-System-in-the-development-of-novel-directly-compressible-co-processed-ex-75x75.jpg)



